FAP and neoplasm: These data are in line with a recent study that investigated a theranostic approach built on a radioligand binding to FAP in tumor mouse models derived from the subcutaneous co-injection of murine tumor cells and immortalized fibroblast cell lines overexpressing human FAP.31 In this investigation, radiopharmaceutical therapy resulted in transiently increased PD-L1 levels on tumor cells and improved anti-tumor efficacy of the radioligand when combined with anti-PD-L1 immune checkpoint therapy.